Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 15, 2021 - Issue 4
Submit an article Journal homepage
319
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Reply to: ‘evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies’

MeiLan K. Hana Pulmonary & Critical Care, University of Michigan, Ann Arbor, MI, USACorrespondence[email protected]
View further author information
,
David A. Lipsonb Clinical Sciences, GlaxoSmithKline, Collegeville, PA, USA;c Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Dave Singhd Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester University NHS Foundation Trust, Manchester, UKView further author information
&
Fernando J. Martineze Pulmonary and Critical Care Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USAView further author information
Pages 577-578 | Received 23 Nov 2020, Accepted 15 Dec 2020, Published online: 28 Dec 2020

References

  • Calzetta L, Ritondo BL, de Marco P. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2020 Sep 14:1–10. Online ahead of print. DOI:10.1080/17476348.2020.1816830.
  • Suissa S. Mortality in IMPACT: confounded by Asthma? Am J Respir Crit Care Med. 2020;202(5):772–773.
  • Lipson DA, Dransfield MT, Han MK. Reply to Suissa: mortality in IMPACT: confounded by Asthma? Am J Respir Crit Care Med. 2020;202(5):773–777.
  • Han MK, Criner GJ, Dransfield MT, et al. The effect of ICS withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study: a randomized, double-blind multicenter trial. Am J Respir Crit Care Med. 2020 Jun 25;202:1237–1243. Online ahead of print.
  • Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
  • Ferguson GT, Rabe K, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758.
  • Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.
  • Martinez FJ, Han MK, Allinson JP, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(12):1540–1551.
  • Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516.
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. [cited 2020 Oct 19]. Available from: https://goldcopd.org
  • Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.